Pharma BD Deal Intelligence
AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer. AstraZeneca will acquire all of Fusion's shares…
AstraZeneca joins radiopharmaceutical deals spree with $2.4B buyout of Fusion, gaining industry-leading radiopharmaceutical R&D, manufacturing, and…
Acquisition of Fusion completed. As a result of the Arrangement, Fusion has become a wholly owned subsidiary of AstraZeneca.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
AstraZeneca acquired Fusion Pharmaceuticals for up to approximately $2.4 billion ($21.00 per share upfront plus $3.00 per share contingent value right) in an all-cash arrangement, gaining next-generation actinium-225-based radioconjugate therapeutics and radiopharmaceutical manufacturing capabilities.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Fusion Pharmaceuticals Inc. (this deal) | 2024 | $2.4B | 64 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2024 deals · AstraZeneca PLC deals · Oncology deals